Established Cardiovascular Disease: Global Prevalence and Trends

What Is "Established" Cardiovascular Disease?

Established cardiovascular disease means a confirmed prior event or diagnosis on the atherosclerotic spectrum. Clinically, this includes prior myocardial infarction (MI), stable or unstable angina, coronary revascularization (PCI or CABG), ischemic stroke or TIA, or symptomatic peripheral arterial disease. The term separates patients who already carry documented atherosclerotic burden from those at elevated risk who have not yet had an event.

Why the Definition Matters for Risk Stratification

Guidelines from the American College of Cardiology and American Heart Association classify any patient with established ASCVD as "very high risk." The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states that patients in this category should receive high-intensity statin therapy and, when LDL-C remains at or above 70 mg/dL, a PCSK9 inhibitor should be considered. [1] That threshold-based approach depends entirely on having a documented diagnosis in the chart.

Distinguishing Established CVD from Subclinical Disease

Subclinical atherosclerosis can be detected by coronary artery calcium (CAC) scoring or carotid intima-media thickness, but these patients carry no confirmed event. Established CVD, by contrast, requires a clinical endpoint. The Global Burden of Disease (GBD) study tracks both as separate entities, which is why GBD prevalence figures for ischemic heart disease tend to be higher than counts based on hospitalization codes alone. [2]

How Many People Have Established CVD Worldwide?

The GBD 2019 analysis estimated 523 million prevalent cases of cardiovascular disease globally. That figure was up 26.6% from 2010. [2] Ischemic heart disease accounted for 197 million of those cases; stroke accounted for 101 million.

Ischemic Heart Disease

Coronary artery disease is the single largest component of established CVD. In 2019, ischemic heart disease caused 8.9 million deaths and generated 182 million DALYs. [2] Global age-standardized prevalence of ischemic heart disease is highest in Eastern Europe and Central Asia, where rates exceed 4,500 per 100,000 population in some subregions.

Stroke

Stroke is the second-largest contributor. The GBD 2019 data place stroke deaths at 6.6 million, with an age-standardized incidence of 132 per 100,000. [2] Hemorrhagic stroke remains more common than ischemic stroke in East Asia, whereas ischemic stroke dominates in North America and Western Europe.

Peripheral Arterial Disease

Peripheral arterial disease (PAD) is often undercounted in global statistics because many patients are asymptomatic. A 2019 Lancet study estimated 236 million people living with PAD globally, with the highest prevalence in sub-Saharan Africa when age is accounted for. [3]

Regional Burden: Where CVD Hits Hardest

More than 75% of all CVD deaths occur in low- and middle-income countries (LMICs). That statistic from the World Health Organization reflects a structural shift that has accelerated since 2000. [4]

High-Income Countries: Declining but Still Dominant

In the United States, the AHA's 2024 Heart Disease and Stroke Statistics Update estimated that approximately 126 million adults (48.6% of the adult population) have some form of CVD, broadly defined to include hypertension. [5] The narrower category of atherosclerotic CVD affects roughly 24.2 million Americans. Age-standardized coronary heart disease mortality in the US fell by approximately 50% between 1990 and 2019, largely attributed to statin use, smoking cessation, and acute revascularization programs.

Western Europe follows a similar trajectory. The European Society of Cardiology reported in its 2021 Atlas that CVD still accounts for 45% of all deaths in Europe, but age-standardized rates have dropped 44% since 1990 in EU-15 countries. [6]

Low- and Middle-Income Countries: A Rising Crisis

South Asia, sub-Saharan Africa, and parts of Latin America are experiencing what epidemiologists call an "epidemiological transition": rising rates of obesity, type 2 diabetes, and hypertension in populations that previously had low CVD burdens. India saw age-standardized CVD mortality increase from 272 to 282 per 100,000 between 2010 and 2019. [2] That modest-sounding rise masks enormous absolute numbers given India's population of 1.4 billion.

China presents a similar picture. Ischemic heart disease deaths in China increased from 948,000 in 1990 to 1.73 million in 2019, a near-doubling driven by urbanization, dietary change, and longer life expectancy. [2]

Sub-Saharan Africa has historically low ischemic heart disease mortality but very high rates of hypertensive heart disease and rheumatic heart disease. Rheumatic heart disease affects approximately 40.5 million people worldwide and kills 306,000 annually, with the vast majority of those deaths occurring in LMICs. [2]

Mortality Trends Over Time

Global age-standardized CVD mortality fell by 27% between 1990 and 2019, from 364 to 266 deaths per 100,000. [2] That reduction is real and clinically meaningful. Yet because the global population grew and aged substantially over the same period, the absolute number of CVD deaths rose from 12.1 million in 1990 to 17.9 million in 2019.

What Drove the Decline in High-Income Countries

Three factors account for most of the mortality reduction in wealthy nations. First, large-scale statin adoption following the 1994 4S Trial (simvastatin, N=4,444) demonstrated a 30% reduction in all-cause mortality in patients with established coronary disease. [7] Second, smoking prevalence fell from approximately 42% of US adults in 1965 to 12.5% in 2020 per CDC data. [8] Third, the door-to-balloon time for STEMI management dropped below 90 minutes as a national standard, limiting infarct size in acute events.

Why Absolute Deaths Keep Rising

Age is the dominant driver. A 65-year-old has roughly five times the absolute risk of a CVD event compared to a 45-year-old, even controlling for all modifiable risk factors. As the global population aged, even a declining age-standardized rate was insufficient to reduce total deaths. The United Nations projects that the global population over age 65 will double by 2050, which makes absolute CVD burden projections grim without aggressive primary prevention. [9]

Projections to 2030 and Beyond

The WHO projects global CVD deaths will reach approximately 23.6 million by 2030 if current trajectories hold. [4] A 2023 analysis in JAMA Cardiology modeling US-specific trends estimated that ASCVD events could increase 31% by 2060 largely due to aging demographics, even assuming continued declines in age-specific rates. [10]

Sex Differences in CVD Prevalence and Outcomes

CVD has long been framed as a male disease. The data tell a more complex story. Globally, ischemic heart disease mortality is higher in men (5.2 million deaths in 2019 vs. 3.7 million in women), but women make up the majority of stroke deaths. [2]

Differences in Presentation and Diagnosis

Women with acute MI more often present without classic chest pain. A 2019 analysis in JAMA Internal Medicine found that women experiencing MI were 59% more likely than men to receive a non-cardiac diagnosis initially, contributing to longer door-to-balloon times and higher in-hospital mortality for STEMI. [11]

Hormonal Transitions as Risk Windows

Menopause accelerates the emergence of CVD risk in women. The average age of natural menopause in the US is 51.4 years. [12] After menopause, LDL-C rises, HDL-C falls, and central adiposity increases, converging to close the sex gap in CVD incidence within a decade. Premature menopause (before age 40) is associated with a 40% higher risk of ischemic heart disease compared to menopause at age 50 to 51, according to a meta-analysis of 301,438 women published in The Lancet. [13]

Diabetes, Obesity, and the Expanding Risk Pool

Established CVD does not occur in a vacuum. It concentrates in people with cardiometabolic risk factors, and those risk factors are becoming more common globally.

Type 2 Diabetes as a CVD Equivalent

The ADA classifies type 2 diabetes with established CVD as a very-high-risk state requiring intensive LDL-C lowering to below 55 mg/dL per some guidelines, or below 70 mg/dL per ADA standards. [14] The UKPDS (N=5,102) established that each 1% reduction in HbA1c over 10 years was associated with a 21% reduction in diabetes-related deaths and a 14% reduction in MI. [15]

Obesity Trends and Cardiovascular Consequences

Global obesity prevalence doubled between 1990 and 2016 per WHO data, and projections suggest more than 50% of adults in many high-income countries will meet obesity criteria by 2030. [4] Obesity independently raises CVD risk through hypertension, dyslipidemia, insulin resistance, and systemic inflammation. The INTERHEART study (N=15,152 MI cases across 52 countries) attributed 20.1% of population-attributable risk for MI to abdominal obesity. [16]

GLP-1 receptor agonists have entered this picture meaningfully. The SELECT trial (semaglutide 2.4 mg, N=17,604 adults with obesity and established CVD but without diabetes) showed a 20% reduction in major adverse cardiovascular events (MACE) at 39.8 months of follow-up compared to placebo. [17] This was the first large trial to show a cardiovascular benefit for a weight-loss agent in a population with established ASCVD.

Socioeconomic Determinants of CVD Burden

Income, education, and neighborhood characteristics shape CVD risk as powerfully as any single laboratory value. A 2020 JAMA analysis of US counties found that counties in the lowest income quintile had coronary heart disease mortality rates 2.4-fold higher than counties in the highest quintile. [18]

Access to Evidence-Based Therapy

In LMICs, access to statins, antihypertensives, and aspirin remains inconsistent. A WHO survey of 47 LMICs found that essential CVD medicines were available in fewer than 50% of public-sector facilities. [4] Even in the US, adherence to secondary prevention medication drops to 50 to 60% at one year post-MI, largely driven by cost and pill burden. [5]

Structural Racism and CVD Disparities

Black Americans have the highest CVD mortality of any racial group in the United States. Age-standardized coronary heart disease mortality in Black men is 20% higher than in White men; in Black women it is 30% higher than in White women per AHA 2024 data. [5] These gaps persist after controlling for traditional risk factors, pointing to chronic stress, environmental exposures, and differential access to care as independent contributors.

Established CVD in Clinical Practice: What the Numbers Mean for Screening and Treatment

Epidemiological data translate into individual clinical decisions. The framework below organizes how global prevalence data should inform practice at three levels.

Population level. A clinician working in Eastern Europe or South Asia should assume higher baseline ASCVD prevalence than a clinician in Japan. Regional calibration of risk calculators matters: the Pooled Cohort Equations were derived primarily from US cohorts and may overestimate risk in some European populations or underestimate it in South Asian ones.

Clinic level. Any patient with a prior MI, stroke, TIA, or revascularization is automatically in the secondary-prevention tier. Guidelines from the ESC (2021) and ACC/AHA (2022) agree that this population should receive high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) regardless of baseline LDL-C. [1, 6]

Individual level. Among patients with established CVD, the residual risk after statin therapy remains substantial. The FOURIER trial (evolocumab, N=27,564) showed that lowering LDL-C from a median of 92 mg/dL to 30 mg/dL further reduced MI and stroke by 27% over 26 months. [19] Risk does not plateau at guideline LDL targets; lower is consistently better in this population.

Key Gaps and Emerging Surveillance Challenges

Global CVD surveillance depends on cause-of-death coding, which is unreliable in settings without universal civil registration. An estimated 50% of deaths in LMICs are registered without medical certification of cause, meaning the 17.9 million figure likely understates true CVD mortality. [2]

Atrial fibrillation adds another layer of complexity. AF affects 59.7 million people globally and substantially raises stroke risk, yet it is not always classified under the CVD umbrella in national registries. A 2021 JAMA Cardiology analysis estimated that AF-related stroke accounts for 15 to 20% of all ischemic strokes in high-income countries. [20]

Remote monitoring and wearable ECG devices could improve early identification of AF and other arrhythmias in populations previously unreachable by traditional care. The Apple Heart Study (N=419,297) detected irregular pulse notifications in 0.52% of participants and confirmed AF in 34% of those who wore a patch monitor, suggesting that large-scale passive surveillance is technically feasible. [21]

The Bottom Line for Patients With Established CVD

Established CVD is a global public health emergency by any reasonable standard. The absolute number of deaths rises each year even as age-standardized rates fall in wealthier nations. Three-quarters of the mortality burden sits in LMICs with limited access to the therapies proven to reduce it. In patients who already carry a diagnosis, the evidence base is clear: high-intensity statins, blood pressure control to below 130/80 mmHg per 2017 ACC/AHA guidelines, antiplatelet therapy where indicated, and consideration of PCSK9 inhibition or GLP-1 receptor agonist therapy when cardiometabolic risk persists. [1, 5] If you have a prior MI, stroke, or revascularization procedure and your most recent LDL-C is above 70 mg/dL, ask your clinician today about adding ezetimibe or a PCSK9 inhibitor to your current regimen.